Trial reportInvestigative ophthalmology & visual science2026
Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy Characterized Using Fundus Autofluorescence: An 18-Month Post Hoc Analysis of GATHER2.
Trial report in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04435366 (A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To identify fundus autofluorescence (FAF) characteristics corresponding to incomplete retinal pigment epithelial and outer retina atrophy (iRORA), defined using optical coherence tomography (OCT), and progression of iRORA to complete lesions (cRORA). Methods: In this GATHER2 (NCT04435366) post hoc analysis, pooled eyes from participants assigned to avacincaptad pegol (2 mg) or sham were analyzed for baseline iRORA beyond the borders of geographic atrophy; each iRORA was assessed for progression to cRORA at months 6, 12, and 18 using OCT. For each OCT-defined lesion at baseline and at each follow-up visit, FAF patterns were defined as none (no autofluorescence abnormalities), not classifiable, increased autofluorescence (IAF), questionably decreased (QDAF), or definite decreased (DDAF). Results: Overall, 153 iRORA from 95 eyes were identified at baseline, and the majority demonstrated none (34.6%; n = 53) or QDAF (34.6%; n = 53) patterns. A smaller proportion of baseline iRORA exhibited a DDAF pattern (7.2%; n = 11). At month 18, the proportion of iRORA manifesting QDAF and DDAF patterns increased to 38.1% and 23.0%, respectively, and the none pattern decreased to 16.8%. The majority of lesions that remained as iRORA at month 18 demonstrated either none (52.8%) or QDAF (49.1%). iRORA that progressed to cRORA by month 18 was more likely to have more advanced FAF abnormalities, with 44.4% having IAF, 30.2% QDAF, and 27.3% DDAF. Conclusions: Findings from this large study reporting FAF characteristics of iRORA highlight the heterogeneity of these lesions and the association of the multimodal phenotype on progression over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.